412 related articles for article (PubMed ID: 25531677)
1. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
[TBL] [Abstract][Full Text] [Related]
2. Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population.
Mojtahedzadeh M; Lee ML; Friedman TC
J Diabetes Complications; 2015; 29(8):1248-52. PubMed ID: 26215435
[TBL] [Abstract][Full Text] [Related]
3. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis.
Wang B; Sun Y; Sang Y; Liu X; Liang J
Medicine (Baltimore); 2018 Nov; 97(46):e12633. PubMed ID: 30431561
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
10. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630
[TBL] [Abstract][Full Text] [Related]
11. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions.
Schöndorf T; Karagiannis E; Posseldt RE; Forst T; Pfützner A
Diabetes Technol Ther; 2009 Jun; 11(6):379-83. PubMed ID: 19459767
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
Takihata M; Nakamura A; Tajima K; Inazumi T; Komatsu Y; Tamura H; Yamazaki S; Kondo Y; Yamada M; Kimura M; Terauchi Y
Diabetes Obes Metab; 2013 May; 15(5):455-62. PubMed ID: 23279373
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Zirie M; Jayyousi A
J Clin Endocrinol Metab; 2017 Jul; 102(7):2162-2170. PubMed ID: 28324038
[TBL] [Abstract][Full Text] [Related]
15. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y; Matsuda M; DeFronzo RA
Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Abe M; Kikuchi F; Kaizu K; Matsumoto K
Clin Nephrol; 2007 Nov; 68(5):287-94. PubMed ID: 18044260
[TBL] [Abstract][Full Text] [Related]
18. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
